Apogee Therapeutics
NASDAQ: APGEFounded 2022 · 2 known investors
Apogee Therapeutics develops novel antibody therapeutics targeting biological drivers of inflammatory and immune diseases, aiming to improve on the standard of care. Its pipeline addresses dermatological, respiratory, and gastroenterological conditions.
Biotech
Investors · 2
Founder mafia
2 people who came through Apogee Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlapBioworld76 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Applied Therapeutics75 shared keywordsApplied Therapeutics is a biopharmaceutical company developing treatments for rare diseases, with a portfolio focused on Classical Galactosemia and CMT-SORD. Its lead investigational drug, govorestat, targets disease pathways such as galactitol and sorbitol reduction.
Companies competing with Apogee Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Apogee Therapeutics do?
- Apogee Therapeutics develops novel antibody therapeutics targeting biological drivers of inflammatory and immune diseases, aiming to improve on the standard of care. Its pipeline addresses dermatological, respiratory, and gastroenterological conditions.
- Who are Apogee Therapeutics's investors?
- Apogee Therapeutics's investors include Access Biotechnology, RA Capital.